Cystic Fibrosis Transmembrane Conductance Regulator-Modifying Medications: The Future of Cystic Fibrosis Treatment

被引:28
|
作者
Pettit, Rebecca S. [1 ]
机构
[1] Indiana Univ Hlth, Riley Hosp Children, Indianapolis, IN USA
关键词
ataluren; CFTR corrector; CFTR modulators; CFTR potentiator; cystic fibrosis; cystic fibrosis transmembrane conductance regulator; ivacaftor; PTC; 124; VX-770; VX-809; INVESTIGATIONAL CFTR POTENTIATOR; PREMATURE STOP MUTATIONS; PHASE-II TRIAL; F508DEL-CFTR MUTATION; G551D-CFTR MUTATION; PTC124; TREATMENT; IN-VITRO; NONSENSE; VX-770; VX-809;
D O I
10.1345/aph.1R076
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To review and evaluate cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). DATA SOURCES: Literature was accessed through MEDLINE (1977-January 2012), the Cochrane Library, and International Pharmaceutical Abstracts (1977-March 2012). Search terms included ivacaftor, VX-770, VX-809, ataluren, PTC 124, CFTR modulator, and cystic fibrosis. STUDY SELECTION AND DATA EXTRACTION: All English-language articles identified from the data sources were evaluated for inclusion. Clinical trials and relevant review articles were evaluated for each CFTR modulator. DATA SYNTHESIS: CF is caused by a mutation in the gene that encodes for the CFTR protein; mutations can be separated into 5 different classes. Ivacaftor is a new CFTR potentiator that helps the CFTR channel open properly in patients with the CFTR mutation, G551D. Patients in one study had significant decreases in sweat chloride values and increases in pulmonary function tests. Ivacaftor was approved by the Food and Drug Administration (FDA) to be taken orally at a dose of 150 mg twice a day in G551D CF patients older than 6 years. Additional studies are investigating the use of ivacaftor in other gating mutations and in younger patients. VX-809 is a CFTR corrector that modulates the folding and trafficking of CFTR. VX-809 was originally studied alone in patients with F508del mutation but is now being used in combination with ivacaftor in Phase 2 studies. Ataluren allows the read through of premature stop codons, and studies in patients with CF with nonsense mutations show an increase in chloride transportation. Ataluren requires 3 times a day dosing and is currently in a Phase 3 placebo-controlled study. CONCLUSIONS: Three new agents, ivacaftor, VX-809, and ataluren, target the basic defects in CFTR production. Ivacaftor was recently FDA approved, while the other 2 agents are still in clinical trials. Patients with CF will benefit from personalized medicine based on their specific genotype.
引用
收藏
页码:1065 / 1075
页数:11
相关论文
共 50 条
  • [31] An unstable transmembrane segment in the cystic fibrosis transmembrane conductance regulator
    Tector, M
    Hartl, FU
    EMBO JOURNAL, 1999, 18 (22): : 6290 - 6298
  • [32] Cystic fibrosis transmembrane conductance regulator—emerging regulator of cancer
    Jieting Zhang
    Yan Wang
    Xiaohua Jiang
    Hsiao Chang Chan
    Cellular and Molecular Life Sciences, 2018, 75 : 1737 - 1756
  • [34] Structure and function of the cystic fibrosis transmembrane conductance regulator
    Morales, MM
    Capella, MAM
    Lopes, AG
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 1999, 32 (08) : 1021 - 1028
  • [35] Evidence for Early Cystic Fibrosis Transmembrane Conductance Regulator Modulator Treatment for Children with Cystic Fibrosis Keeps Growing
    Hoppe, Jordana E.
    Zemanick, Edith T.
    Martiniano, Stacey L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 206 (11) : 1308 - 1310
  • [36] THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE
    TSUI, LC
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 151 (03) : S47 - S53
  • [37] PHOSPHORYLATION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
    PICCIOTTO, MR
    COHN, JA
    BERTUZZI, G
    GREENGARD, P
    NAIRN, AC
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1992, 267 (18) : 12742 - 12752
  • [38] Cystic fibrosis transmembrane conductance regulator and adenosine triphosphate
    Abraham, EH
    Okunieff, P
    Scala, S
    Vos, P
    Oosterveld, MJS
    Chen, AY
    Shrivastav, B
    Guidotti, G
    SCIENCE, 1997, 275 (5304) : 1324 - 1325
  • [39] Pharmacology of CFTR (cystic fibrosis transmembrane conductance regulator)
    Cuthbert, A. W.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 : 22 - 22
  • [40] A transistor model for the cystic fibrosis transmembrane conductance regulator
    Hunt, William D.
    Mccarty, Nael A.
    Marin, Eduardo Martinez
    Westafer, Ryan S.
    Yamin, Phillip R.
    Cui, Guiying
    Eckford, Andrew W.
    Denison, Douglas R.
    BIOPHYSICAL REPORTS, 2023, 3 (02):